Holen Sie sich die Stockscreener-App
35.35
2.85%
0.98
Vorhandelsmarkt:
35.35
Agios Pharmaceuticals Inc Aktie (AGIO) Neueste Nachrichten
Agios Pharmaceuticals, Inc. (AGIO) Backed by TD Cowen for Mitapivat’s Market Potential - MSN
Agios Pharma Increases Shares in Stock Incentive Plan - TipRanks
H.C. Wainwright Maintains a Buy Rating on Agios Pharmaceuticals (AGIO), Reduces PT - MSN
Agios' PYRUKYND Faces FDA Review In SeptemberExpansion Opportunity Ahead? - RTTNews
10 Best NASDAQ Stocks Under $50 to Buy - Insider Monkey
TD Cowen reiterates buy rating on Agios stock ahead of key trial data - Investing.com Canada
Agios Pharmaceuticals Sees Shift in Fund Positioning Russell 1000 - Kalkine Media
10 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey
Agios Pharmaceuticals: A More Compelling Valuation (NASDAQ:AGIO) - Seeking Alpha
Avanzanite annuncia la partnership paneuropea con Agios per lanciare mitapivat nelle malattie ematologiche rare - standard-journal.com
Avanzanite annonce un partenariat paneuropéen avec Agios pour le lancement de PYRUKYND® dans les maladies rares du sang - Eagle-Tribune
Avanzanite gibt europaweite Partnerschaft mit Agios zur Einführung von PYRUKYND® bei seltenen Blutgerinnungsstörungen bekannt - standard-journal.com
Cantor Fitzgerald Predicts AGIO FY2026 Earnings - Defense World
Agios Pharma stock target cut to $56 by H.C. Wainwright - Investing.com Canada
Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders - afp.com
Agios Pharmaceuticals (AGIO) Target Price Revised Amid New Europ - GuruFocus
Agios Pharmaceuticals (AGIO) Target Price Revised Amid New European Deal | AGIO Stock News - GuruFocus
Agios at Goldman Sachs Conference: Strategic Growth in Rare Diseases By Investing.com - Investing.com Canada
Transcript : Agios Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - MarketScreener
Agios stock rises on European distribution deal By Investing.com - Investing.com South Africa
Agios stock rises on European distribution deal - Investing.com Australia
Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders | AGIO Stock News - GuruFocus
California State Teachers Retirement System Trims Stock Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND in Rare Blood Disorders - Business Wire
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $56.50 Average Target Price from Analysts - Defense World
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock Holdings Lowered by Millennium Management LLC - Defense World
Nuveen Asset Management LLC Cuts Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
Ameriprise Financial Inc. Sells 34,140 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
When the Price of (AGIO) Talks, People Listen - news.stocktradersdaily.com
Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025 | AGIO Stock News - GuruFocus
Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025 - The Manila Times
Agios Pharmaceuticals Showcases Rare Disease Breakthroughs at Goldman Sachs Healthcare Conference - Stock Titan
BNP Paribas Financial Markets Sells 2,242 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
What is Zacks Research’s Estimate for AGIO Q2 Earnings? - Defense World
Agios Pharmaceuticals’ SWOT analysis: promising drug pipeline drives stock outlook By Investing.com - Investing.com South Africa
Agios Pharmaceuticals’ SWOT analysis: promising drug pipeline drives stock outlook - Investing.com Canada
Bank of America Corp DE Raises Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded to Sell Rating by StockNews.com - Defense World
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates - MSN
Analysts Update Their Estimates For Agios Pharmaceuticals Inc - Stocksregister
Agios pharmaceuticals outlines key catalysts for PYRUKYND pipeline in 2025 - MSN
Agios Pharma (AGIO) Gets a Buy from Bank of America Securities - The Globe and Mail
Beta thalassemia Market: Epidemiology, Therapies, Companies, - openPR.com
Sickle cell disease Market: Epidemiology, Therapies, - openPR.com
Agios Pharmaceuticals at Bank of America 2025 Healthcare Conference: Strategic Pipeline Advances - Investing.com Canada
Agios to Highlight Pyruvate Kinase Activation Portfolio with New - GuruFocus
Agios Pharmaceuticals (AGIO) Highlights Promising Data at EHA 20 - GuruFocus
Agios Pharmaceuticals (AGIO) Highlights Promising Data at EHA 2025 | AGIO Stock News - GuruFocus
Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress - The Manila Times
New Phase 3 Trial Data: Agios Blood Disorder Treatment Shows Promise in Children and Adults with Rare Diseases - Stock Titan
Northern Trust Corp Purchases 5,372 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
Cantor Fitzgerald maintains AGIOS stock with Overweight rating By Investing.com - Investing.com Canada
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):